Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Lu AF20513 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Lundbeck A/S
- 20 Mar 2018 Planned number of patients changed from 35 to 50.
- 20 Mar 2018 Planned End Date changed from 1 Oct 2018 to 1 Dec 2020.
- 20 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2020.